2010]. In addition, amoxapine has been shown to inhibit several K+ channels including the voltage-gated K+ [He et al. 2010] and the G protein-activated inwardly rectifying K+ (GIRK) channels [Kobayashi et al. 2011] at micromolar concentrations, the same range

as the brain concentration of the drug during treatment (5–67 μM); this effect seems to be mediated through serotonin and dopamine D1/D5 Inhibitors,research,lifescience,medical receptors [Yang et al. 2011]. Amoxapine is metabolized in vivo via CYP2D6 to 7-hydroxyamoxapine, which has affinity for 5-HT2a and D2 receptors. It is also metabolized to 8-hydroxyamoxapine via CYP1A2 [Wong et al. 2012]. These various sites of action on neurotransmitters and ion channels give amoxapine a unique pharmacological profile that may be relevant Inhibitors,research,lifescience,medical for its therapeutic activity and side effects. Tardive dyskinesia and neuroleptic malignant syndrome have been described with amoxapine and attributed to its blockade of DA receptors, while seizures may be related to its activity on ion channels. Amoxapine has demonstrated efficacy in major depressive disorder, with and without psychotic features [Gelenberg et al. 1984; Anton and Burch, 1990]. Its use in schizophrenia is not as well documented. Although one small randomized placebo-controlled study of 10 schizophrenia Inhibitors,research,lifescience,medical patients

did not find improvement after amoxapine [Fitzgerald et al. 2004], an open-label [Apiquian et al. 2003] and two double-blind trials demonstrated efficacy similar to risperidone and haloperidol in the treatment of psychosis, with additional improvement in negative symptoms [selleck Chaudhry et al. 2007; Inhibitors,research,lifescience,medical Apiquian et al. 2005]. Here, we report the improvement, following amoxapine initiation, of positive and negative symptoms in a patient with schizophrenia who had shown lack of clinical response to a robust antipsychotic regimen. This case highlights the use of amoxapine for augmentation with potential to improve positive and Inhibitors,research,lifescience,medical negative

symptoms of schizophrenia. Case presentation The patient is a 26-year-old White female, diagnosed with schizophrenia, paranoid type, since a psychotic episode as a sophomore in college. GSK-3 She presented to our emergency room with local police and was hospitalized, as she was unable to care for herself. She displayed disorganized inhibitor price thoughts with bizarre and persecutory delusions. The patient had four previous admissions: 2004 for psychosis, 2005 for a suicide attempt by overdose, and 2006 and 2010 for psychosis. Admission medications at the time of the first hospitalization were olanzapine, quetiapine, bupropion and escitalopram. Psychotic symptoms improved with haloperidol, followed by haloperidol decanoate and oral risperidone. Bupropion was continued. Divalproex was trialed due to concern for possible bipolarity, but discontinued due to lack of efficacy. Bipolar disorder was not diagnosed. All medications were discontinued during the second hospitalization due to a ‘lack of stated psychotic or mood symptoms’.